Irina Rebin

Prix à l'honneur

JUVE Awards 2023

Law firm of the year for IP Law

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Carrière

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Formation

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Featured

Actualités et publications récentes

View Irina's insights

Cliquer ici pour en savoir plus

Dispositifs médicaux

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

2 juillet 2026

par Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

Medical Cannabis Platforms Breach Advertising Ban

Case law – German Federal Court of Justice (Bundesgerichtshof) – Online platforms brokering medical cannabis treatments breach the prohibition of public advertising under the German Healthcare Advertising Act

2 juillet 2026

Briefing

par Irina Rebin

7 de 9 Publications

Cliquer ici pour en savoir plus

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

CJEU on distributor's verification obligations under MDR

Medical device (and IVD) distributors. CJEU confirms that distributors need not repeat the manufacturer’s classification or conformity assessment, but must perform a “consistency check” for obvious inconsistencies.

1 juillet 2026

Briefing

par Irina Rebin

1 de 9 Publications

Cliquer ici pour en savoir plus

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

Related news & insights

The UPC’s first referral to the European Court of Justice: Cross-border preliminary injunctions against intermediaries and non-UPC defendants

Lettre du CGP n ° 37

Taylor Wessing advises co-lead investor East X Ventures on Proxima Fusion's € 411 million Series A-2 financing round

Hungarian supreme court on legal standing to challenge generic marketing authorisations

Case law – VfGH on the eImpfpass and central vaccination register

The new Product Liability Directive: three life sciences priorities before the 2026 deadline

Poland’s new AI systems act: a regulator and practical tools

France renews its simplified anti-gift conventions – what life sciences companies operating in France need to know

ARIHQ v. Santé Québec: Québec Superior Court set aside an arbitral award due to hallucinating AI

Life Sciences Legal Lens Vol. 2

Autres avocats qui pourraient vous intéresser

Rendez-vous à

Orphan and Breakthrough Devices: A New Route Through the MDR / IVDR Reform

Pharma Perspectives. Connecting Patents, Regulation and Strategy